ADMETRx, a contract research organization that provides in vitro ADME testing support, this week announced a strategic partnership with CeeTox, a CRO that uses in vitro models to predict toxicity.

The alliance is meant to help pharmaceutical and biotech companies improve their drug-discovery decision-making capabilities, a CeeTox official told CBA News.

In the future, CeeTox "would like to build new services with ADMETRx and begin to co-market them," according to a CeeTox official, who did not elaborate.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.